117
In the 18 GCA patients, blood samples were collected at 118 disease onset prior to glucocorticoid therapy and follow-up 119 samples were obtained from 13 patients at 3 months and 120 from six patients at 12 months. Blood samples were col-121 lected from 29 TA patients as a cross-sectional evaluation. (Table   T2 2). 188 6.40 ± 4.50 ng/ml; p = 0.474) or relapsing disease (4.75 ± 189 3.31 ng/ml vs. 6.02 ± 4.47 ng/ml; p = 0.608), respectively.
190
Mean serum HMGB1 levels in GCA patients were 191 5.74 ± 4.19 ng/ml at baseline, 5.18 ± 3.98 ng/ml at 3 192 months, 8.19 ± 6.80 ng/ml at 12 months, and 6.23 ± 2.48 193 ng/ml at the first relapse. During follow-up, no signifi-194 cant fluctuations on serum HMGB1 levels were ob-195 served from baseline levels to 3 and 12 months (Fig.   F2 2). Fig. 1 Serum high mobility group box 1 (HMGB1) levels in patients with giant cell arteritis (GCA) and healthy controls (HC). GCA patients at disease onset present similar serum HMGB1 levels compared to HC Fig. 2 Longitudinal levels of serum high mobility group box 1 (HMGB1) in patients with giant cell arteritis (GCA). Serum HMGB1 in individual GCA patients along follow-up and during relapses (red dots) 
260
The need for reliable biomarkers for disease activity is t3:7 Continuous variables are presented as median and interquartile range or as mean ± standard deviation t3:8 CRP C-reactive protein, ESR erythrocyte sedimentation rate, HMGB1 high mobility group box 1 Fig. 3 Serum high mobility group box 1 (HMGB1) levels in patients with Takayasu arteritis (TA) and healthy controls (HC). TA patients with active disease and in remission present similar serum HMGB1 levels compared with HC Fig. 4 Influence of statins use on serum high mobility group box 1 (HMGB1) levels in patients with Takayasu arteritis (TA). Statins use was associated with significantly lower serum HMGB1 levels in TA patients On the other hand, GCA patients at disease onset and 283 prior to therapy presented serum HMGB1 levels that 284 were similar to those of HC, and no association could be 285 found between HMGB1 and acute phase reactants, dis-286 ease manifestations or disease relapse. Moreover, during 287 follow-up no significant fluctuations in serum HMGB1 288 levels were observed in GCA patients. Novel biomarkers 289 in GCA would help to recognize active disease in pa-290 tients with signs and symptoms of GCA but normal 291 acute phase reactants. However, serum HMGB1 levels 292 were not increased in patients with active disease.
293
Serum HMGB1 levels were significantly higher in 294 GCA patients than in TA patients, and even though the 295 ROC analysis showed that a cutoff value of 2.17 ng/ml 296 in HMGB1 levels would help to differentiate GCA from 297 TA, we believe that it is unlikely that in clinical practice 298 it would replace the 50-year-old cutoff point used to dif-299 ferentiate both entities [1] . Furthermore, GCA controls 300 had higher serum HMGB1 than TA controls. The role of statins in GCA has still to be determined.
329
No impact on relapse rate or on the prevention of severe 330 ischemic events was observed in retrospective studies. 
334
In TA patients, a retrospective study could not find any 335 difference in ischemic events between patients with and 336 without statins but associations with disease activity were 337 not analyzed [45] . In the present study, more TA patients 338 used statins than GCA patients at diagnosis although this 339 difference was not statistically significant (data not shown).
340
This could be due to the long disease course of our TA pa- 
